-
TelaBio – ReBAR – Ovitex
Here are some interesting new things from TelaBio, the developers of Ovitex. People who have been around for a few years might remember that Ovitex was fairly well promoted on this forum, with Dr. Towfigh mentioning it often. Not so much anymore, it’s not even clear if she still uses it.
Regardless, TelaBio has developed a new method of repair, that seems to be focused on finding a new way to use Ovitex. As is similar with their other studies the time frame is relatively short, with just 157 “hernias”. Not clear how many patients. The method apparently uses robotic laparoscopic techniques to suture the hernia defect from the inside then cover the sutured defect with Ovitex. It makes you wonder if the sutures alone would be enough. Where is the control study? Why does the “standard” method of mesh implantation not work with Ovitex? Can this new method be used with synthetic meshes? There does not seem to be a publication of any kind beyond this press release. Anything goes, it seems, in inguinal hernia repair.
Anyway, it’s fascinating to try to keep up with these technology companies’ efforts to grow their markets. I wonder if anyone will attempt a pure tissue repair via Robotic TAP. that would be impressive.
From the press release –
“Robotic Reinforced Biologic Augmented Repair (ReBAR) of Over 150 Inguinal Hernias: 2-Year Outcomes
AHS presentation on Wednesday, September 14th, 11:20-11:30 a.m.ET
This retrospective study examined the two-year recurrence rate of the robotic-assisted reinforced biologic augmented repair (ReBAR) of inguinal hernias from June 2018 to April 2022. All repairs employed the standard robotic transabdominal preperitoneal (rTAPP) approach combined with the novel ReBAR technique, which consists of suture closure of the defect followed by a biologic mesh reinforcement. After two years, only three recurrences were identified from the 157 inguinal hernias repaired using the ReBAR technique – a rate of 1.9%, and only two SSOs were identified in this cohort.”
Log in to reply.